Literature DB >> 19712010

The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Jasmina I Ivanova1, Howard G Birnbaum, Seth Samuels, Matthew Davis, Amy L Phillips, Dennis Meletiche.   

Abstract

Studies have not previously reported the indirect cost burden of multiple sclerosis (MS) from an employer perspective. To compare annual indirect costs between privately insured US employees with MS and matched employee controls. A retrospective analysis of a privately insured claims database containing disability data from 17 US companies was conducted. Employees with >/=1 MS diagnosis (ICD-9-CM: 340.x) after 1 January 2002, aged 18-64 years, were selected. Employees with MS were matched by age and sex to employee controls without MS. All were required to have continuous health coverage 3 months before MS diagnosis (baseline) and 12 months after (study period). Main outcomes measures included study period annual indirect (disability and medically related absenteeism) costs. For completeness, we also included measures of direct (medical and drug) costs. Chi-squared tests were used to compare baseline co-morbidities and differences in indirect resource use (disability and medically related absenteeism) between employees with MS and controls. Wilcoxon rank-sum tests were used for univariate comparisons of disability and medically related absenteeism days and associated annual indirect and direct costs between employees with MS and controls. Generalized linear models, controlling for differences in baseline characteristics, were used to estimate risk-adjusted annual costs for employees with MS and controls. Employees with MS (n = 989) averaged 44 years of age, and 66% were female. Compared with employee controls, employees with MS had significantly higher rates of mental health disorders, other neurological disorders and physical disorders measured by the Charlson Co-morbidity Index. Employees with MS were more likely to have short-term or long-term disability than employee controls (21.4% vs 5.2%, respectively; p < 0.0001), resulting in a higher mean number of disability days per year (29.8 vs 4.5; p < 0.0001). Employees with MS also had a higher rate of medically related absenteeism and associated absenteeism days than employee controls. On average, annual costs (year 2006 values) for disability were significantly higher for employees with MS ($US3868) than employee controls ($US414; p < 0.0001). Annual medically related absenteeism costs were also higher for employees with MS than for controls ($US1901 vs $US1003, respectively; p < 0.0001). On average, total annual indirect costs for employees with MS were $US5769 compared with $US1417 for controls (p < 0.0001). MS is a chronic and debilitating disease that poses a substantial employer burden in terms of medically related absenteeism and disability costs. Indirect costs of employees with MS were >4 times those of employee controls.

Entities:  

Mesh:

Year:  2009        PMID: 19712010     DOI: 10.2165/11314700-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  32 in total

1.  Prevalence, expenditures, utilization, and payment for persons with MS in insured populations.

Authors:  G C Pope; C J Urato; E D Kulas; R Kronick; T Gilmer
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

2.  Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Authors:  R A Rudick; D E Goodkin; L D Jacobs; D L Cookfair; R M Herndon; J R Richert; A M Salazar; J S Fischer; C V Granger; J H Simon; J J Alam; N A Simonian; M K Campion; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; R H Whitham
Journal:  Neurology       Date:  1997-08       Impact factor: 9.910

3.  A chronic disease score from automated pharmacy data.

Authors:  M Von Korff; E H Wagner; K Saunders
Journal:  J Clin Epidemiol       Date:  1992-02       Impact factor: 6.437

4.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Prevalence estimates for MS in the United States and evidence of an increasing trend for women.

Authors:  Curtis W Noonan; Steven J Kathman; Mary C White
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

7.  Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; C C Ford; A Goodman; J Guarnaccia; R P Lisak; L W Myers; H S Panitch; A Pruitt; J W Rose; N Kachuck; J S Wolinsky
Journal:  Mult Scler       Date:  2000-08       Impact factor: 6.312

8.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

9.  Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group.

Authors:  D N Bourdette; A V Prochazka; W Mitchell; P Licari; J Burks
Journal:  Arch Phys Med Rehabil       Date:  1993-01       Impact factor: 3.966

10.  Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability.

Authors:  Virginia Casado; Sergio Martínez-Yélamos; Antonio Martínez-Yélamos; Olga Carmona; Lucia Alonso; Lucia Romero; Esther Moral; Laura Gubieras; Txomin Arbizu
Journal:  BMC Health Serv Res       Date:  2006-11-01       Impact factor: 2.655

View more
  14 in total

1.  Economic burden of epilepsy among the privately insured in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Yohanne Kidolezi; Ying Qiu; David Mallett; Sue Caleo
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Understanding Drivers of Employment Changes in a Multiple Sclerosis Population.

Authors:  Karin S Coyne; Audra N Boscoe; Brooke M Currie; Amanda S Landrian; Todd L Wandstrat
Journal:  Int J MS Care       Date:  2015 Sep-Oct

3.  Burden of a multiple sclerosis relapse: the patient's perspective.

Authors:  Merrikay Oleen-Burkey; Jane Castelli-Haley; Maureen J Lage; Kenneth P Johnson
Journal:  Patient       Date:  2012       Impact factor: 3.883

Review 4.  Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA.

Authors:  Daniel M Hartung
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

5.  Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate.

Authors:  Amber Salter; Samantha Lancia; Gary Cutter; Robert J Fox; Ruth Ann Marrie; Jason P Mendoza; James B Lewin
Journal:  Int J MS Care       Date:  2021-07-09

6.  Occupational outcomes of people with multiple sclerosis: a scoping review.

Authors:  Bruno Kusznir Vitturi; Alborz Rahmani; Guglielmo Dini; Alfredo Montecucco; Nicoletta Debarbieri; Elvira Sbragia; Paolo Bandiera; Michela Ponzio; Mario Alberto Battaglia; Tommaso Manacorda; Benedetta Persechino; Giuliana Buresti; Matilde Inglese; Paolo Durando
Journal:  BMJ Open       Date:  2022-07-01       Impact factor: 3.006

7.  Patient perceptions of multiple sclerosis and its treatment.

Authors:  Jérôme de Seze; Florent Borgel; Frédérique Brudon
Journal:  Patient Prefer Adherence       Date:  2012-04-04       Impact factor: 2.711

8.  Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey.

Authors:  Hillary J Gross; Crystal Watson
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-18       Impact factor: 2.570

9.  Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data.

Authors:  Jacqueline Nicholas; Aaron Boster; Ning Wu; Wei-Shi Yeh; Monica Fay; Jon Kendter; Ming-Yi Huang; Andrew Lee
Journal:  Pharmacoecon Open       Date:  2018-03

10.  The MS@Work study: a 3-year prospective observational study on factors involved with work participation in patients with relapsing-remitting Multiple Sclerosis.

Authors:  Karin van der Hiele; Dennis A M van Gorp; Marco A P Heerings; Irma van Lieshout; Peter J Jongen; Michiel F Reneman; Jac J L van der Klink; Frans Vosman; Huub A M Middelkoop; Leo H Visser
Journal:  BMC Neurol       Date:  2015-08-12       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.